Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.
However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.
Recent Posts
Advancements in Intranasal Drug Delivery: Hovione and IDC Launch Commercial Platform
Hovione and IDC have announced that their Intranasal Drug Delivery platform has advanced to commercial readiness, with the lead single-use nasal dry powder device now available for partnerships. This integrated solution combines API development, particle engineering, formulation, capsule filling,...
Portugal Cannabis Market Decline: Analyzing the Impact of Licensing Reductions
The Portugal cannabis market decline has accelerated sharply since January 2026. Official Infarmed IP lists show that more than 30 percent of entities authorised for medicinal cannabis activities in Portugal have been suspended or permanently removed, producing a measurable contraction across cul...
NICE Approves Durvalumab for Gastric Cancer Treatment
NICE has issued final draft guidance recommending durvalumab, within its marketing authorisation, for use with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment, followed by durvalumab monotherapy as adjuvant treatment, in adults with ...